Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics (NASDAQ: VVOS) has launched VivoScore, a home sleep apnea test utilizing advanced cardiopulmonary technology by SleepImage. This single-sensor device connects to a mobile app, facilitating clinical-grade sleep apnea diagnosis. The pilot study indicated that 56% of tested patients had OSA, with 50% pursuing treatment through the Vivos System. This innovation is expected to lower costs and enhance diagnosis accessibility for untreated sleep apnea patients, addressing a market of roughly 1 billion individuals worldwide. VivoScore is anticipated to significantly boost patient enrollment and revenue for Vivos Therapeutics.
Vivos Therapeutics (NASDAQ: VVOS) announced the formation of a Clinical Advisory Board to enhance the adoption of its innovative treatments for obstructive sleep apnea (OSA), which affects 1 billion people worldwide. The board comprises distinguished experts from sleep medicine and dentistry, bringing decades of experience to ensure the Vivos System remains a leading non-surgical treatment. This move aims to strengthen Vivos' market position and drive further commercial success, leveraging the expertise of its members.
Vivos Therapeutics (NASDAQ: VVOS) has launched its new patient management software, AireO2, aimed at improving the diagnosis and treatment of obstructive sleep apnea (OSA). With around 1 billion people affected by OSA, the software enhances healthcare professionals’ billing services and operational efficiency. CEO Kirk Huntsman emphasized that AireO2 will help manage more patients effectively. The platform is poised to drive revenue for Vivos beyond its existing services, potentially addressing the needs of OSA-focused healthcare providers.
Vivos Therapeutics announced the closing of its IPO, issuing 4,025,000 shares at $6.00 each, yielding gross proceeds of $24.15 million. The offering included 3,500,000 initial shares plus 525,000 additional shares from underwriters’ options. Roth Capital Partners led the offering, with Craig-Hallum Capital Group and National Securities Corporation as co-managers. The SEC had declared the registration effective on December 10, 2020, with a final prospectus filed on December 14, 2020. Vivos specializes in non-invasive solutions for sleep disordered breathing.